Biotech Startups
9,920 companies tagged Biotech, with their investors and founders.
NMD Pharma is a clinical-stage biotech company developing first-in-class small-molecule therapies that selectively target skeletal muscle to treat rare neuromuscular diseases and age-related conditions. Its lead candidate, ignaseclant (NMD670), is in clinical development for Charcot-Marie-Tooth disease, generalized myasthenia gravis, and spinal muscular atrophy.</parameter> <parameter name="founders">[]
2 investors
Nosis develops a platform for receptor-targeted delivery of RNA therapeutics to specific cell types, addressing a key bottleneck in RNA drug development. The company aims to reduce the cost and timeline of bringing new RNA medicines to market.
2 investors
Nostopharma develops targeted nanodelivery technology and advanced molecular interventions for bone and soft tissue disorders, using precision medicine approaches to repurpose existing drugs. The company serves clinicians treating patients with conditions like heterotopic ossification and cartilage damage.
2 investors
Nourish Ingredients develops animal-free fats and lipids using precision fermentation, including Tastilux (a fungal-fermentation phospholipid for meaty flavour) and Creamilux (a short-chain lipid emulsifier for dairy mouthfeel). It supplies these high-potency fat ingredients to food manufacturers and brands making alternative meat and plant-based or hybrid dairy products.
2 investors
Novai applies advanced molecular and computational approaches to eye disease, supporting clinicians and researchers in translating scientific findings into patient treatment options.
2 investors
NovalGen is a clinical-stage biotechnology company developing multi-specific biologics for oncology, autoimmune, haematological, and metabolic disorders using its proprietary AutoRegulation platform technology.
2 investors
2 investors
Novo Nordisk is a pharmaceutical company that develops and markets treatments for conditions including diabetes, obesity/weight management, and haemophilia, with products such as GLP-1 therapies. It serves patients and healthcare markets globally.
2 investors
Novocure develops Tumor Treating Fields therapy for treating aggressive forms of cancer. The company focuses on patient-centered innovation in oncology.
2 investors
Novotech is a contract research organization (CRO) that provides clinical trial execution and scientific advisory services for biotech and biopharma sponsors, including complex cell and gene therapy trials. It has a strong regional focus on the Asia-Pacific market.
2 investors
NSG Bio operates BSL-2 certified co-working wet-laboratory and office spaces for life sciences and biotech companies in Singapore, offering turnkey facilities, shared equipment, and support services for startups and multinationals conducting R&D. It also runs a sponsorship and grant program for early-stage biotech ventures, with locations at Biopolis and the Geneo Life Sciences Cluster at Singapore Science Park.
2 investors
NTx Bio develops proprietary cell-free synthetic biology platforms for on-demand, decentralized biomanufacturing of mRNA and proteins. The company serves drug developers and researchers seeking faster, scalable production of therapeutic molecules from concept to commercial manufacturing.
2 investors
Nuage Therapeutics develops drug discovery technologies for disordered proteins, focusing on precision treatments for aggressive cancers with limited therapeutic options. The company targets disease-causing protein targets rooted in human biology.
2 investors
Nuanced Health develops healthcare solutions, though the specific product focus is not detailed on this team page.
2 investors
Nuclera provides multiplex protein screening technology for life science researchers, enabling faster access to and testing of proteins for drug discovery and development. The company serves protein scientists and research teams accelerating breakthroughs in structural biology and functional studies.
2 investors
A specialty pharmaceutical company focused on developing and commercializing novel therapeutics for central nervous system conditions, serving patients and healthcare providers.
2 investors
Nunatak develops microbial solutions to improve soil-plant health and help crops thrive under stress conditions, informed by plant-microbiome relationships from extreme environments. The company serves agriculture and land restoration through biological products designed to regenerate soils.
2 investors
Nuntius develops programmable nanocarriers for drug delivery that can target tissues beyond the liver and utilize machine learning to optimize carrier performance. The company serves pharmaceutical and biotech organizations developing targeted therapeutics.
2 investors
Nusano produces medical radioisotopes for use in theranostic compounds and cancer treatment applications. The company serves the healthcare and oncology sectors by making radioisotopes available for targeted radiopharmaceutical therapies.
2 investors
NuSirt Sciences develops therapies that activate the sirtuin pathway by combining established pharmaceuticals and natural products to treat cardiometabolic conditions of aging and overnutrition, including fatty liver disease (MAFLD/MASH), obesity, type 2 diabetes, and hypertension. Its lead drug candidate TRIPLN combines L-leucine, metformin, and sildenafil, and it also markets LEUSIX, a dietary supplement for cardiometabolic health and weight management.
2 investors
2 investors
2 investors
ObjectiveHealth brings clinical trials into local physician practices by integrating technology with electronic health records to identify and match patients to relevant studies. It serves physicians, community health centers, patients, and pharmaceutical sponsors seeking tech-enabled clinical research collaborations.
2 investors
Oblenio Bio develops LBL-051, a tri-specific T-cell engager therapy targeting BCMA, CD19, and CD3 for treating refractory autoimmune diseases through B-cell and plasma cell depletion. The company aims to achieve long-term drug-free remission in autoimmune disease patients.
2 investors